BHI Q&A with 3i Diagnostics, Inc. President & CEO, Jim Janicki & Chief Technology Officer, Rajesh Krishnamurthy
Company: 3i Diagnostics, Inc. “3iDx” www.3iDx.com
Location: Germantown Innovation Center/Launch Labs
Overview: 3iDx is an early stage company developing a new technology platform that is able to isolate and analyze microbes directly from samples for the purpose of identifying antimicrobial resistant strains in less than an hour without having to wait for up to a week for blood culture results. Their ultimate aim is to create a 15-minute test that runs in a battery powered handheld device.
Goal: Our goal is to enable true precision medicine for infection. We see this as the largest single global healthcare issue today, as measured in lives and dollars.
Sucampo’s (NASDAQ:SCMP) share price has been stuck in a range for a considerable time, but the company wasn’t idle - management has been working hard to move the company away from its legacy product Amitiza into rare diseases. Sucampo made two transactions since early 2016 and now has two late-stage orphan assets (one wholly owned and an option on the other) with data readouts in 2018. Sucampo is generating strong free cash flow and expects to continue to build out its late-stage orphan drug pipeline. Meanwhile, Amitiza has been growing at a steady pace and that’s despite the growing competition in the constipation space. I believe that cash flow from Amitiza provides downside protection while the orphan pipeline stands to add significant value in the long run.
The day after emocha® Mobile Health, Inc., launched in 2013, CEO Sebastian Seiguer (pronounced SAY-ger) heard about a 3-year-old tuberculosis (TB) patient being treated at a Baltimore clinic. Maryland requires healthcare providers to watch patients take every dose of their medication for active TB treatment, an approach known as directly observed therapy (DOT). But coordinating with the clinic every day was proving too difficult for the girl's mother to manage. To keep up with the treatments, she would have had to quit her job.
Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial. ZIKV-VLA1601, which has shown to elicit functional antibody responses, is based on Valneva's established inactivated, whole virus manufacturing platform on which its licensed Japanese Encephalitis vaccine was developed and produced.
The University System of Maryland (USM) has named business innovator David W. Wise, MALD, as director of the Maryland Momentum Fund (MMF), a $25 million fund to support startups formed within the system’s 12 institutions and its incubators. He joined USM on July 24.
The University of Maryland, Baltimore (UMB) has been selected as one of "The Great Colleges to Work For" by The Chronicle of Higher Education. The results of its national survey, which were released in the magazine’s Academic Workplace supplement that came out July 21, lauded UMB in the categories of collaborative governance, compensation and benefits, and confidence in senior leadership.
GlaxoSmithKline (GSK) is axing 130 'non-core' brands and overhauling its prescription drugs business to focus on products that deliver stronger returns.
It is also stepping up a cost reduction program that has already bitten into media and marketing budgets across the consumer healthcare portfolio.
AstraZeneca and Merck & Co. announced on July 27, 2017 that they have entered a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor for treating BRCA-mutated ovarian cancer in multiple lines of treatment. It was approved by FDA in December 2014 and generated 2016 sales of $218 million.
The Inova Personalized Health Accelerator (IPHA) is preparing to accept applications from early-stage startups focused on predicting, preventing and treating disease. Falls Church-based Inova Health System announced plans for the accelerator last December when it also launched Inova Strategic Investments, a venture-capital program. Both projects are housed at the new Inova Center for Personalized Health, a 117-acre campus in Fairfax County.
In the craft-beer industry, the majority of hops — the flowers used in production that add bitterness and aroma to the product — come from the Pacific Northwest region.
Could Maryland, too, be a fertile region for hops?
GlaxoSmithKline will cut more than 30 drug development programmes and may sell its rare diseases unit, as the FTSE 100 group seeks to inject more “edge and pace” into its decision making, its new chief executive Emma Walmsley has said.
No area is hotter or attracting more dollars in pharma than immuno-oncology–the idea of harnessing the immune system to fight cancer. My fellow Forbes contributor Bruce Booth has recently characterized the intensifying interest in this space as the “exploding supernova” of cancer research.
IonQ, an early-stage company developing quantum computing for commercial applications, today announced completion of a $20 million series B round led by New Enterprise Associates (NEA) and GV (formerly Google Ventures), with participation from new strategic investors. Building on the pioneering work of world-renowned experts at the University of Maryland and Duke University, IonQ plans to bring general-purpose quantum computers to market by late 2018.
Calling All Medical Device Innovators!
We are now accepting proposals for our annual $250K pediatric medical device pitch competition. Up to six innovations will be awarded up to $50,000 each during our 5th Annual Pediatric Surgical Innovation Symposium.
Registration Open – 5th Annual Pediatric Device Innovation Symposium We are pleased to announce that our 5th annual Pediatric Device Innovation Symposium, “Partnering for Breakthroughs in Pediatric Surgery and Care,” is co-locating in San Jose, California in a joint effort with The MedTech Conference powered by AdvaMed – the premiere gathering of medtech professionals in North America.
Join us Sunday, September 24, 2017
Here are some of the event highlights:
Keynotes and panels on topics related to pediatric device innovation Make your Medical Device Pitch for Kids! competition - $250K in funding Invaluable networking opportunities to meet, learn and get inspired by your fellow medtech innovators Special savings when you attend the Symposium and The MedTech Conference
The Galien Foundation announced today the 2017 Annual Prix Galien USA Awards Nominees.
Worldwide regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research, the Prix Galien recognizes outstanding biomedical and technology product achievement that improves the human condition.
Canaan has put together an $800 million investment fund. The fund positions Canaan to place a fresh round of bets on early-stage biotechs, continuing the strategy that has delivered it paydays as companies including Johnson & Johnson and Teva have snapped up pieces of its portfolio.
Global University Venturing’s last issue before the summer provides an opportunity to look back at the first six months of the year – as the data reveals, it has been a busy period with activity picking up significantly towards the end of the second quarter.
That increased activity, however, appears not to have translated into a boost for the total amount of capital raised compared with the same period last year. Although there were 44 deals in June, they amounted to only $365.3m of transaction value – a drop of nearly $90m from May.
Australian biotech, Trimph, has successfully completed a first-in-human trial of its proprietary bone “glue”, TrimphDent, the only bone graft substitute in the world to be applied in liquid form, halving the time of patient recovery, and requiring no specialised preparation or additional surgical expertise.
This breakthrough will allow Trimph to progress towards registering TrimphDent and launching into global markets, which could provide significantly more affordable and accessible oral surgeries to rural and disadvantaged communities across the globe.
The global population will increase to almost ten billion by 2050 while greenhouse gas emissions from agriculture continue to rise. We need to intensify food production while shrinking agriculture’s impact on the environment. Canadian biotechnology is helping farmers produce more food while simultaneously reducing the environmental footprint of agriculture.
Last Friday, the emocha team onboarded two of our newest video DOT partners: San Diego County and the State of Delaware. From Collin County, TX, to Columbus, OH, we’ve continued working with innovative tuberculosis programs to make directly observed therapy more convenient and cost-effective.
We're taking all opportunities as we grow to gather user feedback and improve the emocha experience for patients and providers. That’s why earlier this month, our team visited the Puerto Rico Department of Health to learn how our technology has impacted their TB program.
In late 2016, the island was dealing with a TB outbreak in a facility for mentally impaired men. We volunteered the emocha platform pro bono to help manage the outbreak with Dr. Dana Thomas, then Medical Director, championing the effort on behalf of the TB program. Within months, all patients using emocha showed clinical signs of improvement.
“emocha is so important because we have lost staff and fiscal resources over the years,” said Dr. Olga Joglar, TB Control Program Director.
In Puerto Rico and around the country, emocha helps public health departments save time and money on DOT programs. NIH-supported research shows that our platform for video observation can secure 92% adherence with significant cost savings.
READ MORE FROM THE NIH
The emocha platform is used worldwide for TB, HCV, HIV and opioid use disorder treatment. Ready to learn more? Visit our website or reach out at email@example.com
About the Cluster Action Plan TOHealth! brought together diverse participants from Human Health and Sciences ecosystem in the Toronto region to develop Ontario’s first draft Cluster Action Plan under the Partnerships for Jobs and Growth Act. The draft Plan has been approved by the Minister of Economic Development and Growth / Research Innovation and Science and is now subject to a 30 day public consultation. Please download the draft documents using links above and share your comments using the button below. The consultation period ends August 11, 2017.
A new type of trial design can help the healthcare industry bring beneficial therapies to patients sooner and stop researching inferior ones earlier.
Value has found a place at the heart of healthcare innovation. For money-conscious governments and other actors in the system, it’s not enough that a new treatment be beneficial and safe. It also needs to be cost effective.
As the White House and the US Congress continue to lock horns over President Donald Trump's proposed budget, scientists are once again anxious about funding levels. But more money is not enough to create better science. Indeed, the scientific enterprise has been betrayed by the mismanagement of its financial support.
The road to launching a life science start-up can be a long and difficult one, with founders often struggling to secure funding and manage the logistics of setting up a business. In a move to encourage innovation and help start-ups hit the ground running, there are an increasing choice of accelerator and support programs becoming available.
We spoke to Giovanni Rizzo, PhD MBA Chief of Innovation Division, Z-Cube S.r.l. to learn more about such programs and the difference they can make to innovation, as well as share some tips for academics beginning a start-up venture.